Morgan Stanley resumed coverage of Genmab (GMAB) with an Equal Weight rating and $34 price target following the company’s acquisition of Merus. After incorporating lead asset, petosemtamab, into the firm’s model and updating its Epkinly build, the firm will be looking for key catalysts across both programs in 2026, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility
- GMAB Upcoming Earnings Report: What to Expect?
- Genmab Grants New RSUs and Warrants to Employees to Strengthen Long-Term Incentives
- AI Daily: Nvidia invests $2B in CoreWeave
- Drugmakers use AI to help progress through trials, submissions, Reuters says